Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by SrPlataon Nov 16, 2021 8:06pm
222 Views
Post# 34134340

Why I bought More Arch at All Time Highs

Why I bought More Arch at All Time HighsI bot More ACHFF today at $3.03 and last week at $2.95 raising my Avg Cost Basis per share to $1.37.  Why????
1. As Champs just mentioned the data is going to be good, they would have had to disclose by now if it was not. 
2. Still way undervalued, thanks Riverfolk for your constant updates in comparisons to other Biotechs and valuation metrics.
3. As I have mentioned many times but bares repeating for investors new to this stock. The Institution are not heavily involved because of liquidity issues only 62mm shares out and Insiders and Family and Friends owning around 63% and savvy long time holders who are not interested in selling until we enter  P3 
4. I am betting on the Canadian Health Ministry funding P3 for Lungs, why not they funded P2. I don't think most investors are factoring that in. 
5. Once P3 is announced your going to see the stock skyrocket, how high it goes i really don't know but in this market with so much money out there, and the low float of shares. I would be disappointed with anything less than $10USD.
6. When this happens and we see analyst pick up coverage then I believe management will go to the capital markets to raise money for P3 for the Kidneys that is the $20biilon market for AKI
7. Now Wall Street will know about ARCH and they will have the Institutional sponsorship they need to get stock price a lot higher.
8. Then there will be buyout talk by Big Pharma, why ARCH will be in control is because of the high insiders ownership of 55%, they know what they have and they know the potential, and we own the technology, it is not licensed out by a University or other 3rd party
9. Chart wise there is no overhead resistants it is clear sailing, if you want it you have to pay up for it.

There is more reasons than those I listed above to buy Arch BioPartners right now but those are my main one's. And that is  why I have been buying at All Time Highs
<< Previous
Bullboard Posts
Next >>